Extension of SFB1399


Funding for worldwide largest research consortium on Small Cell Lung Cancer extended for four additional years

The German Research Council (or, DFG) has accepted the application for extension of Collaborative Research Center 1399 (CRC1399, or, SFB1399, www.sfb1399.de) for funding of its scientific work. CRC1399 was launched in 2019 as the worldwide largest concerted research effort on Small Cell Lung Cancer. The additional funding of more than 12 million Euro will enable extending the work of CRC1399 through 2027.

Small Cell Lung Cancer is a highly lethal cancer affecting roughly 300,000 individuals annually. Unfortunately, most treatments lead to an only marginal prolongation of survival of the affected patients. CRC1399 was launched as a multi-institutional and interdisciplinary attack on this cancer type with the goal of discovering novel mechanisms of disease and entry routes for new medicines.

CRC1399 includes more than 100 scientists from almost 30 laboratories working at 7 scientific institutions and covers a wide range of research areas, such as cancer genomics, computational biology, chemical biology, cell death and inflammation, signal transduction, imaging, pathology and clinical medicine. The unique setup of the consortium enables deeply interwoven research, thus affording scientific breakthroughs at the interface of the various disciplines and areas of expertise.

“We are very pleased about the DFG’s decision and are grateful to the reviewers for all the time and effort they have put into the review of our initiative” said Prof Roman Thomas, M.D., speaker of CRC1399 and director of the Department of Translational Genomics at the University of Cologne. “It is a testament to the quality of the science that has emerged from the hard work of all the researchers of our CRC. Together with my fellow co-speakers, Julie George, Silvia von Karstedt, Christian Reinhardt and Ugur Sahin, we will continue to strive to enable exciting discoveries, that ultimately, we hope, will aid patients suffering from this terrible disease.”


For more information, please visit www.sfb1399.de or contact

Dr. Graziella Bosco, Scientific Coordinator SFB1399 and DTG







Twitter: @sfb1399 and @DTG_Cologne

LinkedIn: linkedin.com/in/department-of-translational-genomics-429167227